Patents by Inventor Murray A. Kaplan
Murray A. Kaplan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070133754Abstract: A system and method are provided for modifying an existing HDSL system to allow for remote access to performance monitoring information stored on each HDSL circuit card. This is accomplished by attaching a cable harness to an existing chassis. A cable harness containing a number of data lines equal to the number of circuit cards in the chassis is housed in a moveable bar which protects the harness and allows removal or insertion of HDSL circuit cards. Each data line attaches to a data port on the individual circuit cards, and the cable harness terminates to a multiplexer (shelf multiplexing unit). A system controller unit provides power and signaling to the shelf multiplexing unit, instructing the multiplexing unit to select an individual data line connected to an individual circuit card. Then utilizing a mutually agreed upon communications means, the system controller unit extends the HDSL data port connection to a remote location.Type: ApplicationFiled: December 9, 2005Publication date: June 14, 2007Applicant: Telecom Assistance Group, Inc.Inventors: Murray Kaplan, Kenneth Kaplan, Paul Lorey
-
Patent number: 6455575Abstract: The present invention concerns antitumor compounds. More particularly, the invention provides novel taxane derivatives, pharmaceutical compositions thereof, and their use as antitumor agents.Type: GrantFiled: June 6, 1997Date of Patent: September 24, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Jerzy Golik, Dolatrai Vyas, John J. Wright, Henry Wong, John F. Kadow, John K. Thottathil, Wen-Sen Li, Murray A. Kaplan, Robert K. Perrone, Mark D. Wittman
-
Publication number: 20010023255Abstract: The present invention concerns antitumor compounds. More particularly, the invention provides novel taxane derivatives, pharmaceutical compositions thereof, and their use as antitumor agents.Type: ApplicationFiled: June 6, 1997Publication date: September 20, 2001Inventors: JERZY GOLIK, DOLATRAI VYAS, JOHN J. WRIGHT, HENRY WONG, JOHN F. KADOW, JOHN K. THOTTATHIL, WEN-SEN LI, MURRAY A. KAPLAN, ROBERT K. PERRONE, MARK D. WITTMAN
-
Patent number: 6207650Abstract: Provided are very highly water soluble, stable, crystalline salts of 2′,3′-dideoxy-2′,3′-didehydrothymidine (“d4T”), 2′,3′-dideoxyinosine (“ddI”), and 2′,3′-dideoxy-2′-fluoroinosine (“F-ddI”). Such salts are useful as intermediates or as antiviral agents.Type: GrantFiled: December 6, 1991Date of Patent: March 27, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Joseph B. Bogardus, Murray A. Kaplan, Robert K. Perrone
-
Patent number: 5646176Abstract: The present invention concerns antitumor compounds. More particularly, the invention provides novel taxane derivatives, pharmaceutical compositions thereof, and their use as antitumor agents.Type: GrantFiled: May 19, 1995Date of Patent: July 8, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Jerzy Golik, Dolatrai Vyas, John J. Wright, Henry Wong, John F. Kadow, John K. Thottathil, Wen-Sen Li, Murray A. Kaplan, Robert K. Perrone, Mark D. Wittman
-
Patent number: 5608048Abstract: The present invention concerns a novel process using controlled cooling for obtaining d.sub.4 T polymorphic Form I from a mixture containing one or more of polymorphic Forms I, II and III. Compound d.sub.4 T has been approved for use in the treatment of AIDS.Type: GrantFiled: June 5, 1995Date of Patent: March 4, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Rajesh B. Gandhi, Joseph B. Bogardus, Peter M. Garofalo, Timothy R. Marr, Robert K. Perrone, Murray A. Kaplan
-
Patent number: 5455270Abstract: Solutions of carboplatin and other malonato platinum(II) antitumor agents are prepared containing stabilizing amounts of 1,1-cyclobutanedicarboxylic acid or salt at pH 4-8. The stabilizers inhibit unacceptable discoloration and precipitation. The solutions may also be stabilized by purging the carrier with air or oxygen and, optionally, blanketing the headspace with air or oxygen.Type: GrantFiled: August 11, 1993Date of Patent: October 3, 1995Assignee: Bristol-Myers Squibb Co.Inventors: Murray A. Kaplan, Lawan Phusanti, Robert K. Perrone, Scott R. Stenberg, Sheeram Agharkar, Joseph B. Bogardus
-
Patent number: 5401842Abstract: The present invention provides physical admixtures of a new crystalline dihydrochloride dihydrate salt of the cephalosporin antibiotic, cefepime with a pharmaceutically acceptable non-toxic organic or inorganic base. In particular, this invention provides physical admixtures having a temperature and moisture stable crystalline dihydrochloride dihydrate form of cefepime having a specific X-ray powder diffraction pattern as described herein.Type: GrantFiled: February 18, 1994Date of Patent: March 28, 1995Assignee: Bristol-Myers Squibb CompanyInventors: Munir N. Nassar, Murray A. Kaplan
-
Patent number: 5391729Abstract: The present invention relates to a new crystalline dihydrochloride dihydrate salt of the cephalosporin antibiotic, cefepime. In particular, this invention provides a temperature and moisture stable crystalline dihydrochloride dihydrate form of cefepime having enhanced stability and a specific x-ray powder diffraction pattern as described herein.Type: GrantFiled: May 28, 1993Date of Patent: February 21, 1995Assignee: Bristol-Myers Squibb CompanyInventors: Elizabeth A. Garofalo, Gary M. F. Lim, Murray A. Kaplan
-
Patent number: 5244891Abstract: Crystalline sulfuric, di-nitric, mono-hydrochloric, di-hydrochloric, and di- and sesqui-orthosphosphoric acid addition salts of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(Z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinio)methyl]-3-cephem-4-carboxylate are stable even at elevated temperatures. The crystalline sulfuric acid addition salt is made by forming an admixture of (a) at least one molar equivalent of sulfuric acid with (b) zwitterion in an amount so as to be present in the admixture at a concentration of greater than 25 milligrams/ml, causing crystallization, separating the crystals, washing and drying. The crystalline monohydrochloride, dihydrochloride, and orthophosphate salts are prepared by dissolving the zwitterion in the appropriate amount of acid, causing crystallization by adding acetone and isolating the crystals. Physical admixtures of the salts with certain bases in proportions to give a pH ranging from about 3.Type: GrantFiled: May 22, 1992Date of Patent: September 14, 1993Assignee: Bristol-Myers Squibb CompanyInventors: Murray A. Kaplan, Thomas W. Hudyma, Robert A. Lipper, Kun M. Shih, Susan D. Boettger
-
Patent number: 5196555Abstract: Platinum complexes are disclosed in which the formula is ##STR1## wherein A and B are each independently ammine or monodentate amine, or A and B taken together represent a bidentate amine, and A and B are coordinated to the platinum atom through their nitrogen atom; X and Y are each independently halogen; R' is C.sub.1 -C.sub.20 alkanoyl, aroyl, heteroaroyl, or a group selected from the group consisting of ##STR2## wherein u' is an integer from 1 to 5; and R" is hydrogen with the proviso that A, B, X, and Y are structually equatorial substituents with respect to OR'--Pt--OR". These platinum complexes show antitumor activity with relatively lower kidney or bone marrow toxicity.Type: GrantFiled: December 13, 1991Date of Patent: March 23, 1993Assignee: Bristol-Myers Squibb CompanyInventors: Murray A. Kaplan, Robert K. Perrone, Joseph B. Bogardus, Kenneth J. Wilcox
-
Patent number: 5157718Abstract: An interface adapter is disclosed for utilization with a conventional toll operator position system having a keyboard, video display and controller which interface adapter interface with the TOPS position and external data bases and audio response units in a manner to permit the TOPS position to additionally perform such functions as directory assistance, order entry and line message delivery. The interface adapter includes first and second switching means to intercept the keyboard and video data paths of the TOPS position to isolate the controller and includes a control processor in communication with the external data bases and audio response units which is programmed to respond upon command from the keyboard to access the external data bases and audio response units as required and to communicate such data or audio response to the appropriate terminus.Type: GrantFiled: November 29, 1989Date of Patent: October 20, 1992Inventors: Murray Kaplan, Jeffrey R. Segal
-
Patent number: 5095011Abstract: A stable, amorphous, lyophilized dihydrochloride salt of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinium) methyl]-3-cephem-4-carboxylate is described. This lyophilized salt is more easily prepared than the crystalline counterpart and can be reconstituted in effective concentrations for intramuscular and intravenous injection utilizing suitable organic and inorganic bases to pH 3-7.0.Type: GrantFiled: December 20, 1990Date of Patent: March 10, 1992Assignee: Bristol-Myers CompanyInventors: Murray A. Kaplan, Munir N. Nassar
-
Patent number: 5036010Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.Type: GrantFiled: April 26, 1990Date of Patent: July 30, 1991Assignee: Bristol-Myers CompanyInventors: King S. Lam, Jacqueline Mattei, John E. Leet, James A. Matson, Koji Tomita, Murray A. Kaplan
-
Patent number: 5034397Abstract: This invention relates to novel compositions of the antitumor agent [4'-9-(acridinylamino) methanesulfon-m-anisidide], (m-AMSA). Acid salts of m-AMSA are dissolved in 1-methyl-2-pyrrolidinone to provide highly stable solutions. The solutions may be diluted with Sterile Water for Injection, U.S.P. to provide stable, non-precipitating solutions for intravenous use.Type: GrantFiled: December 12, 1985Date of Patent: July 23, 1991Assignee: Bristol-Myers Squibb Co.Inventors: Murray A. Kaplan, Robert A. Lipper
-
Patent number: 5023904Abstract: A direct telephone dialing ordering system and method is disclosed wherein a calling customer can order products and/or services from a given vendor without voice interchange. The system operates in a local Access and Transport Area (LATA) switching network which has Feature Group D services utilizing a predetermined dialing plan. The system is positioned within the LATA and is assigned a Feature Group D interexchange carrier number. In accordance with the dialing plan of the Feature Group D service, certain digits of the originating call are utilized to direct the call to the system within the LATA to a point of termination wherein the system appears as an interexchange carrier. The system is then free to utilize the remaining digits of the originating call for determination of variables such as vendor, product, grade and the like designations.Type: GrantFiled: October 12, 1989Date of Patent: June 11, 1991Assignee: Science Dynamics CorporationInventors: Murray Kaplan, Robert W. Humes
-
Patent number: 4994271Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.Type: GrantFiled: February 16, 1988Date of Patent: February 19, 1991Assignee: Bristol-Myers CompanyInventors: Kin S. Lam, Jacqueline Mattei, John E. Leet, James A. Matson, Koji Tomita, Murray A. Kaplan
-
Patent number: 4994451Abstract: Crystalline sulfuric, di-nitric, mono-hydrochloric, di-hydrochloric, and di- and sesqui-orthosphosphoric acid addition salts of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(Z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinio)methyl]-3-cephem-4-carboxylate are stable even at elevated temperatures. The crystalline sulfuric acid addition salt is made by forming an admixture of (a) at least one molar equivalent of sulfuric acid with (b) zwitterion in an amount so as to be present in the admixture at a concentration of greater than 25 milligrams/ml, causing crystallization, separating the crystals, washing and drying. The crystalline monohydrochloride, dihydrochloride, and orthophosphate salts are prepared by dissolving the zwitterion in the appropriate amount of acid, causing crystallization by adding acetone and isolating the crystals. Physical admixtures of the salts with certain bases in proportions to give a pH ranging from about 3.Type: GrantFiled: December 11, 1989Date of Patent: February 19, 1991Assignee: Bristol-Myers CompanyInventors: Murray A. Kaplan, Thomas W. Hudyma, Robert A. Lipper, Kun M. Shih, Susan D. Boettger
-
Patent number: 4946689Abstract: The invention relates to chemically stable, concentrated solutions of cis-diamminedinitratoplatinum which are pH-stabilized with nitric acid and are readily convertible to parenteral cisplatin solutions by addition of sources of chloride ion.Type: GrantFiled: November 23, 1988Date of Patent: August 7, 1990Assignee: Bristol-Myers CompanyInventors: Murray A. Kaplan, Robert K. Perrone, Joseph B. Bogardus, Kenneth W. Douglas, Sr.
-
Patent number: 4927638Abstract: A solution of etoposide in dimethylisosorbide is disclosed. The solution is useful for filling gelatin capsules and may also be formulated into parenteral dosage forms.Type: GrantFiled: September 12, 1988Date of Patent: May 22, 1990Assignee: Bristol-Myers CompanyInventors: Gururaj Bykadi, Murray A. Kaplan, Richard G. Corrao, Edward J. Bara, Ismat Ullah, Shreeram N. Agharkar